SAB Biotherapeutics Inc (SABS) - Net Assets
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has net assets worth $214.78 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($238.21 Million) and total liabilities ($23.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SABS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $214.78 Million |
| % of Total Assets | 90.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | 292.98% |
| 10-Year Change | N/A |
| Growth Volatility | 197.8 |
SAB Biotherapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how SAB Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is SAB Biotherapeutics Inc worth.
Annual Net Assets for SAB Biotherapeutics Inc (2019–2025)
The table below shows the annual net assets of SAB Biotherapeutics Inc from 2019 to 2025. Also explore SAB Biotherapeutics Inc (SABS) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $151.49 Million | +483.35% |
| 2024-12-31 | $25.97 Million | -54.68% |
| 2023-12-31 | $57.30 Million | +84.49% |
| 2022-12-31 | $31.06 Million | -19.43% |
| 2021-12-31 | $38.55 Million | -1.17% |
| 2020-12-31 | $39.01 Million | +1791.90% |
| 2019-12-31 | $-2.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SAB Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7879297400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.77K | 0.00% |
| Other Comprehensive Income | $186.51K | 0.12% |
| Other Components | $262.20 Million | 173.07% |
| Total Equity | $151.49 Million | 100.00% |
SAB Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of SAB Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Tianhe Agricultural Means
SHE:002999
|
$319.42 Million |
|
Daeduck Co. Ltd.
KO:008060
|
$319.46 Million |
|
Zhejiang Yangfan New Materials Co Ltd
SHE:300637
|
$319.47 Million |
|
Materialise NV
NASDAQ:MTLS
|
$319.66 Million |
|
Banvit Bandirma Vitaminli Yem Sanayi AS
IS:BANVT
|
$319.24 Million |
|
Thoresen Thai Agencies Public Company Limited
BK:TTA
|
$319.17 Million |
|
Computer Direct
TA:CMDR
|
$319.15 Million |
|
Ercros
MC:ECR
|
$319.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SAB Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 25,969,576 to 151,494,375, a change of 125,524,799 (483.4%).
- Net income of 13,273,683 contributed positively to equity growth.
- New share issuances of 168,729,827 increased equity.
- Other comprehensive income increased equity by 321,920.
- Other factors decreased equity by 56,800,631.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $13.27 Million | +8.76% |
| Share Issuances | $168.73 Million | +111.38% |
| Other Comprehensive Income | $321.92K | +0.21% |
| Other Changes | $-56.80 Million | -37.49% |
| Total Change | $- | 483.35% |
Book Value vs Market Value Analysis
This analysis compares SAB Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.53 | $3.51 | x |
| 2020-12-31 | $14.44 | $3.51 | x |
| 2021-12-31 | $14.10 | $3.51 | x |
| 2022-12-31 | $7.14 | $3.51 | x |
| 2023-12-31 | $10.38 | $3.51 | x |
| 2024-12-31 | $2.80 | $3.51 | x |
| 2025-12-31 | $2.47 | $3.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SAB Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.76%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (8.76%) is above the historical average (-35.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -261.07% | 0.19x | 0.00x | $-8.76 Million |
| 2020 | 51.57% | 36.42% | 0.98x | 1.45x | $16.22 Million |
| 2021 | -44.47% | -28.16% | 0.75x | 2.10x | $-21.00 Million |
| 2022 | -60.34% | -78.40% | 0.47x | 1.64x | $-21.85 Million |
| 2023 | -73.64% | -1884.50% | 0.03x | 1.46x | $-47.92 Million |
| 2024 | -131.33% | -2579.03% | 0.03x | 1.70x | $-36.70 Million |
| 2025 | 8.76% | 0.00% | 0.00x | 1.14x | $-1.88 Million |
Industry Comparison
This section compares SAB Biotherapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $182,883,608
- Average return on equity (ROE) among peers: -77.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SAB Biotherapeutics Inc (SABS) | $214.78 Million | 0.00% | 0.11x | $319.36 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $117.14 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $318.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.59 Billion |
| Arbutus Biopharma Corp (ABUS) | $200.23 Million | -28.52% | 0.14x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $9.17 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $4.70 Billion |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more